Form 8K Gain Therapeutics Inc For: 17 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gain Therapeutics Inc (GANX)
Gain Therapeutics Inc stock price live, this page displays NASDAQ GANX stock exchange data. View the GANX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Gain Therapeutics Inc real time stock price chart below.
What Is the Gain Therapeutics Inc Stock Price Today?
The Gain Therapeutics Inc stock price today is 1.480.
What Is the Stock Symbol for Gain Therapeutics Inc?
The stock symbol for Gain Therapeutics Inc is ""GANX.""
What Stock Exchange Does Gain Therapeutics Inc Trade On?
Gain Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Gain Therapeutics Inc a Good Stock to Buy?
Determining whether Gain Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GANX quote. (ISIN: US36269B1052)
What Is the Gain Therapeutics Inc Stock Price Today?
The Gain Therapeutics Inc stock price today is 1.480.
What Is the Stock Symbol for Gain Therapeutics Inc?
The stock symbol for Gain Therapeutics Inc is ""GANX.""
What Stock Exchange Does Gain Therapeutics Inc Trade On?
Gain Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Gain Therapeutics Inc a Good Stock to Buy?
Determining whether Gain Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GANX quote. (ISIN: US36269B1052)
NASDAQ
Currency in USD
1.480
-0.010(-0.67%)
Closed·
After Hours
1.600+0.120(+8.11%)
·
Fair Value
An estimate of a Gain Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.462
1.530
52 wk Range
0.890
3.190
GANX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
1/2
Fair Value
An estimate of a Gain Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.4621.530
52 wk Range
0.8903.190
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GANX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Gain Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
8.000
Upside
+440.54%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Gain Therapeutics Inc Company Profile
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher’s disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Gain Therapeutics Inc SWOT Analysis
Innovative Approach | Gain Therapeutics pioneers protein misfolding treatments, targeting neurodegenerative diseases with proprietary allosteric binding site technology |
Financial Landscape | With $16.9M cash runway into 2025, GANX faces funding challenges. Analyst price targets range from $5 to $10, suggesting significant upside potential |
Clinical Milestones | Phase 1 trial progress for GT-02287 in GBA-Parkinson's disease sets stage for Phase 1b initiation in Q4 2024, crucial for validating technology |
Market Opportunity | Projected peak revenues of $800M by 2040 highlight vast potential in neurodegenerative treatments, balanced against fierce competition and development risks |
Compare GANX to Peers and Sector
Metrics to compare | GANX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGANXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.4x | −3.1x | −0.5x | |
PEG Ratio | −0.06 | 0.00 | 0.00 | |
Price/Book | 8.9x | 2.7x | 2.6x | |
Price / LTM Sales | - | 150.6x | 3.3x | |
Upside (Analyst Target) | - | 196.4% | 43.4% | |
Fair Value Upside | Unlock | 5.5% | 7.1% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.000
(+440.54% Upside)
Earnings
Latest Release
May 14, 2025
EPS / Forecast
-0.16 / -0.186
Revenue / Forecast
-- / 25.00K
People Also Watch
FAQ
What Stock Exchange Does Gain Therapeutics Trade On?
Gain Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Gain Therapeutics?
The stock symbol for Gain Therapeutics is "GANX."
What Is the Gain Therapeutics Market Cap?
As of today, Gain Therapeutics market cap is 51.17M.
What Is Gain Therapeutics's Earnings Per Share (TTM)?
The Gain Therapeutics EPS (TTM) is -0.82.
When Is the Next Gain Therapeutics Earnings Date?
Gain Therapeutics will release its next earnings report on 06 Nov 2025.
From a Technical Analysis Perspective, Is GANX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Gain Therapeutics Stock Split?
Gain Therapeutics has split 0 times.
How Many Employees Does Gain Therapeutics Have?
Gain Therapeutics has 24 employees.
What is the current trading status of Gain Therapeutics (GANX)?
As of 10 Aug 2025, Gain Therapeutics (GANX) is trading at a price of 1.48, with a previous close of 1.49. The stock has fluctuated within a day range of 1.46 to 1.53, while its 52-week range spans from 0.89 to 3.19.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.